piperazine has been researched along with Idiopathic Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, S | 1 |
| Kumari, R | 1 |
| Sophronea, T | 1 |
| Kumari, N | 1 |
| Luthra, PM | 1 |
| Neustadt, BR | 1 |
| Hao, J | 1 |
| Lindo, N | 1 |
| Greenlee, WJ | 1 |
| Stamford, AW | 1 |
| Tulshian, D | 1 |
| Ongini, E | 1 |
| Hunter, J | 1 |
| Monopoli, A | 1 |
| Bertorelli, R | 1 |
| Foster, C | 1 |
| Arik, L | 1 |
| Lachowicz, J | 1 |
| Ng, K | 1 |
| Feng, KI | 1 |
2 other studies available for piperazine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Design and synthesis of benzo[d]thiazol-2-yl-methyl-4-(substituted)-piperazine-1-carbothioamide as novel neuronal nitric oxide inhibitors and evaluation of their neuroprotecting effect in 6-OHDA-induced unilateral lesioned rat model of Parkinson's disease
Topics: Animals; Enzyme Inhibitors; HEK293 Cells; Humans; Mammals; Neurons; Nitric Oxide; Nitric Oxide Synth | 2022 |
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; | 2007 |